Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FTn-ICG is a nanoparticle-based imaging agent composed of indocyanine green (ICG), a near-infrared fluorescent dye, encapsulated within or conjugated to ferritin nanocages. Ferritin is a naturally occurring protein that forms hollow spherical structures capable of carrying various payloads. By loading ICG into these nanocages (FTn), the resulting complex improves the stability and bioavailability of ICG for in vivo imaging applications. The primary mechanism involves passive targeting and enhanced fluorescence for real-time visualization during surgical procedures or diagnostic imaging. This formulation aims to overcome limitations of free ICG such as rapid clearance and instability in aqueous solutions, providing improved contrast and longer circulation time for fluorescence-guided surgery or vascular/lymphatic mapping.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FTn-ICG.